Immunosuppression

 


Abbreviated medical protocols from EdREN, the website of the Renal Unit of the Royal Infirmary of Edinburgh

Important: Protocol superseded July 2009 - see new version here at www.edren.co.uk.
That website is in development - you can ignore the 'This website is not ready' signs ONLY for the Transplant protocols. Others are not updated or fully transferred.

Methyl Prednisolone 500 mg IV just prior to releasing clamps and again at 24 hours.

Standard immunosuppression will be Tacrolimus (FK506) led triple therapy.

Patients who have an increased risk of rejection will receive Tacrolimus led triple therapy, but with MMF substituted for Azathioprine.


 

High risk Patients Include:

  • Previously sensitised patients - those with panel reactive antibody titres of > 50%.
  • FACS +ve crossmatch
  • B cell +ve crossmatch
  • More than one transplant in the past
  • Past episodes of graft loss due to acute rejection
  • HLA mismatch - non favourable


Basiliximab

May also be given to patients with expected delayed graft function to allow reduced Tacrolimus dose (0.05mg/kg/day given as two doses), and sometimes to patients believed to be at increased risk of rejection.


Links

Treatment of acute rejection

 

 

Transplant protocols developed on the Edinburgh Transplant Unit. This page first published March 2002 by Amit Adlakha, updated November 2006 and last modified Tuesday, August 11, 2009.

NOTE that the accuracy of any statements in this information CANNOT be guaranteed. It is published in the belief that it is correct, and we endeavour to keep it so - but we do make mistakes. Furthermore, over some subjects there are differing opinions, or differing degrees of certainty. We have usually not attempted to discuss these here because the aim has been to provide an immediate and brief guide. In all areas, prior medical knowledge is assumed. The EdRenHANDBOOK is not suitable for use by those without such a background. Contact us by email or at the address given at the foot of the contents page with any comments or corrections.

 


Go to top of page


Go back to EdRenHANDBOOK contents page


Go to EdREN home page